Table 1.
Treatment effect for the primary composite endpoint and the secondary endpoints of cardiovascular death and heart failure hospitalization.
| Placebo N = 2524 | Vericiguat N = 2526 | Treatment comparison | |||||
|---|---|---|---|---|---|---|---|
| n (%) | Event rate: % of patients/year1 | n (%) | Event rate: % of patients/year1 | Hazard ratio (95% CI)2 | P value3 | Absolute risk reduction4 | |
| Primary endpoint | |||||||
| Composite of cardiovascular death or heart failure hospitalization5 | 972 (38.5) | 37.8 | 897 (35.5) | 33.6 | 0.90 (0.82, 0.98) | 0.019 | 4.2 |
| Secondary endpoints | |||||||
| Cardiovascular death | 441 (17.5) | 13.9 | 414 (16.4) | 12.9 | 0.93 (0.81, 1.06) | ||
| Heart failure hospitalization | 747 (29.6) | 29.1 | 691 (27.4) | 25.9 | 0.90 (0.81, 1.00) | ||
1Total patients with an event per 100 patient years at risk. 2Hazard ratio (VERQUVO over placebo) and confidence interval from a Cox proportional hazards model. 3From the log-rank test. 4Absolute risk reduction, calculated as difference (placebo-VERQUVO) in event rate per 100 patient years. 5For patients with multiple events, only the first event contributing to the composite endpoint is counted. N = number of patients in intent-to-treat (ITT) population; n = number of patients with an event.